Reaching COPD stability predicted about half the later risk of exacerbation and death

Design

Post hoc analyses of phase 3 randomised trials (IMPACT, FULFIL, MATINEE/METREX/METREO)

Population

Patients with COPD on triple or dual inhaled therapy, with or without mepolizumab

Primary outcome

Achievement of stability and subsequent exacerbation and mortality risk

Effect

Stability 18–46%; stable at week 28: −45.7% exacerbation risk, −51.7% all-cause mortality risk

This post hoc analysis used IMPACT and FULFIL (single-inhaler triple therapy against dual therapy) and MATINEE, METREX and METREO (mepolizumab added to triple therapy). Stability was defined as no moderate or severe exacerbation and no worsening from baseline in COPD Assessment Test score or FEV1.

Stability was achieved by 22% on triple therapy in IMPACT at 52 weeks, 46% in FULFIL at 24 weeks, and 18% on mepolizumab plus triple therapy at 52 weeks. It was more likely with triple than dual therapy and with mepolizumab than placebo. In IMPACT, patients stable at week 28 had a 45.7% lower risk of later moderate or severe exacerbation and a 51.7% lower risk of death than those who were not.

COPD management has long focused on treating exacerbations. It proposes stability as a composite goal; whether escalating treatment to reach it improves outcomes has not been tested, and escalation should still follow GOLD criteria. The source trials were industry-sponsored, and stability here is associated with, not proven to cause, the better outcomes.

• Consider stability (no exacerbations, no worsening in CAT or FEV1) as a proposed goal; when it is not reached, review adherence, inhaler technique and diagnosis first.
• Stability was more often achieved in patients randomised to triple than to dual therapy.
• Eosinophilic COPD not stable on triple therapy may be considered for a biologic where available.
• Only about one in five to one in two patients achieved stability; most need ongoing review.

Why it matters

It proposes a treat-to-target goal for COPD like those already used in asthma and rheumatoid arthritis.

Don't overread it

This is a post hoc analysis of industry trials; stability predicted outcomes but was not tested as a treatment strategy.

The statistics, in plain English

The 46% and 52% risk reductions compare patients who achieved stability with those who did not. That is prognostic, not causal: patients who become stable may differ in ways that also protect them. It does not show that chasing stability improves survival.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.